Lab21 to Provide Cancer Test for Patients Taking Amgen Drug | GenomeWeb
NEW YORK (GenomeWeb News) – Amgen said today that it has partnered with Lab21 to launch a new genetic test for patients in the UK taking Amgen’s Vectibix (panitumumab) for advanced bowel cancer.
 
The screening test was developed by British molecular diagnostics firm DxS, which sells a range of cancer mutation diagnostic products.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.